Description: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Home Page: www.claritypharmaceuticals.com
CU6 Technical Analysis
National Innovation Centre
Sydney,
NSW
2015
Australia
Phone:
61 2 9209 4037
Officers
Name | Title |
---|---|
Dr. Alan John Taylor Ph.D. | Exec. Chairman |
Dr. Colin David Biggin Ph.D. | MD, CEO & Exec. Director |
Mr. David K. Green BEc., CA | Chief Financial Officer |
Mr. Robert Vickery | Company Sec. |
Dr. Michael D. Ironside | Director of Operations |
Dr. Jeffrey Norenberg | Chief Scientific Officer |
Dr. Ellen van Dam Ph.D. | Head of R&D |
Mr. Shaemus Gleason | Exec. VP of US Operations |
Dr. Robert M. Miller Ph.D. | Consultant Chief Medical Officer |
Mr. William Cheadle | Financial Controller |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 2.7448 |
Price-to-Sales TTM: | 38.334 |
IPO Date: | |
Fiscal Year End: | June |
Full Time Employees: | 0 |